128 related articles for article (PubMed ID: 15831235)
1. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.
Phuphanich S; Baker SD; Grossman SA; Carson KA; Gilbert MR; Fisher JD; Carducci MA
Neuro Oncol; 2005 Apr; 7(2):177-82. PubMed ID: 15831235
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
Gilbert J; Baker SD; Bowling MK; Grochow L; Figg WD; Zabelina Y; Donehower RC; Carducci MA
Clin Cancer Res; 2001 Aug; 7(8):2292-300. PubMed ID: 11489804
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
Grossman SA; Carson KA; Phuphanich S; Batchelor T; Peereboom D; Nabors LB; Lesser G; Hausheer F; Supko JG;
Neuro Oncol; 2008 Aug; 10(4):608-16. PubMed ID: 18577560
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
7. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
Peereboom DM; Supko JG; Carson KA; Batchelor T; Phuphanich S; Lesser G; Mikkelsen T; Fisher J; Desideri S; He X; Grossman SA;
J Neurooncol; 2010 Nov; 100(2):261-8. PubMed ID: 20449631
[TBL] [Abstract][Full Text] [Related]
9. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
Chang SM; Kuhn J; Wen P; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; Cloughesy T; De Angelis L; Razier J; Hess K; Dancey J; Prados MD;
Invest New Drugs; 2004 Nov; 22(4):427-35. PubMed ID: 15292713
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
11. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
Phuphanich S; Carson KA; Grossman SA; Lesser G; Olson J; Mikkelsen T; Desideri S; Fisher JD;
Neuro Oncol; 2008 Aug; 10(4):617-23. PubMed ID: 18477765
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
Kuhn JG; Chang SM; Wen PY; Cloughesy TF; Greenberg H; Schiff D; Conrad C; Fink KL; Robins HI; Mehta M; DeAngelis L; Raizer J; Hess K; Lamborn KR; Dancey J; Prados MD;
Clin Cancer Res; 2007 Dec; 13(24):7401-6. PubMed ID: 18094423
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of GRN1005 in recurrent malignant glioma.
Drappatz J; Brenner A; Wong ET; Eichler A; Schiff D; Groves MD; Mikkelsen T; Rosenfeld S; Sarantopoulos J; Meyers CA; Fielding RM; Elian K; Wang X; Lawrence B; Shing M; Kelsey S; Castaigne JP; Wen PY
Clin Cancer Res; 2013 Mar; 19(6):1567-76. PubMed ID: 23349317
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KD; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):87-94. PubMed ID: 20150371
[TBL] [Abstract][Full Text] [Related]
17. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
Carducci MA; Gilbert J; Bowling MK; Noe D; Eisenberger MA; Sinibaldi V; Zabelina Y; Chen TL; Grochow LB; Donehower RC
Clin Cancer Res; 2001 Oct; 7(10):3047-55. PubMed ID: 11595694
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.
Rudek MA; New P; Mikkelsen T; Phuphanich S; Alavi JB; Nabors LB; Piantadosi S; Fisher JD; Grossman SA
J Neurooncol; 2011 Nov; 105(2):375-81. PubMed ID: 21547395
[TBL] [Abstract][Full Text] [Related]
20. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
Grossman SA; Carson KA; Batchelor TT; Lesser G; Mikkelsen T; Alavi JB; Phuphanich S; Hammour T; Fisher JD; Supko JG
Clin Cancer Res; 2006 Sep; 12(17):5174-81. PubMed ID: 16951236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]